Drug Shortage Report for TRAVASOL
Report ID | 146106 |
Drug Identification Number | 00872296 |
Brand name | TRAVASOL |
Common or Proper name | Amino Acids (Blend C) Injection |
Company Name | BAXTER CORPORATION |
Market Status | MARKETED |
Active Ingredient(s) | LEUCINE SERINE TYROSINE PROLINE ARGININE GLYCINE L-ALANINE TRYPTOPHAN THREONINE HISTIDINE VALINE ISOLEUCINE L-LYSINE METHIONINE PHENYLALANINE |
Strength(s) | 730MG 500MG 40MG 680MG 1.15G 1.03G 2.07G 180MG 420MG 480MG 580MG 600MG 580MG 400MG 560MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 1000 mL (JB6584) |
ATC code | B05BA |
ATC description | I.V. SOLUTIONS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2021-09-23 |
Estimated end date | 2021-10-01 |
Actual end date | 2021-10-01 |
Shortage status | Resolved |
Updated date | 2021-10-02 |
Company comments | Baxter is experiencing supply constraints due to the shortage of Travasol 10% 3000mL (DIN 00872296). As a result this product has been placed on allocation at 100% of historical usage. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2021-10-02 | English | Compare |
v5 | 2021-10-01 | French | Compare |
v4 | 2021-10-01 | English | Compare |
v3 | 2021-09-24 | English | Compare |
v2 | 2021-09-23 | French | Compare |
v1 | 2021-09-23 | English | Compare |
Showing 1 to 6 of 6